A Post-Intervention Surveillance Study Regarding the Acquisition Rate of ESBL-KP, Ecoli

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00724919
First received: July 23, 2008
Last updated: August 7, 2008
Last verified: August 2008
  Purpose

To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, post- intervention in the selected medical centres


Condition
Infection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) (A Post-Intervention Surveillance Study)

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of surveillance phase [ Time Frame: 48hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The infection rate due to ESBL producing E. coli, or due to K. pneumoniae at the end of surveillance phase [ Time Frame: 48hours ] [ Designated as safety issue: No ]

Enrollment: 256
Study Start Date: December 2003
Study Completion Date: April 2004
Primary Completion Date: April 2004 (Final data collection date for primary outcome measure)

Detailed Description:

This is post-interventional study to follow the acquisition rate of ESBP producing E. coli or K. pneumoniae at the sites involved in a previous interventional study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients admitted to ICU/burn unit

Criteria

Inclusion

  1. All patients admitted or transferred to ICU/burn unit.
  2. Patients of either sex, 18 years of age or older. Exclusion

Patients were excluded if they had underlying conditions or diseases that were ultimately fatal within 48 hours

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00724919

Locations
Taiwan
Miaoli County, Taiwan, 351
Taichung, Taiwan, 40705
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

Responsible Party: Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
ClinicalTrials.gov Identifier: NCT00724919     History of Changes
Other Study ID Numbers: 0910X-101440
Study First Received: July 23, 2008
Last Updated: August 7, 2008
Health Authority: Taiwan: Department of Health

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
ESBL

ClinicalTrials.gov processed this record on October 23, 2014